We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
Read MoreHide Full Article
Key Takeaways
Vertex will buy CRNX for about $10B, adding approved drug Palsonify and multiple endocrine pipeline assets.
VRTX expects the deal to boost revenues immediately and adjusted operating income beginning in 2029.
Vertex says acquired assets have peak annual sales potential above $5B, led by Palsonify and atumelnant.
Vertex Pharmaceuticals (VRTX - Free Report) announced that it has agreed to acquire commercial-stage company Crinetics Pharmaceuticals . Per the terms, the large-cap biotech will acquire all outstanding shares of CRNX for $85 per share, valuing the deal at around $10 billion.
Following the acquisition, Vertex will add Palsonify — Crinetics’ first marketed drug and the first once-daily oral therapy for adults with acromegaly, a rare and debilitating condition caused by a pituitary tumor that secretes excess growth hormone. Approved by the FDA in September 2025 and across the EU in April 2026, Palsonify has demonstrated encouraging early commercial uptake and is expected to benefit from Vertex's global commercial infrastructure.
The company will also add several pipeline candidates, including Crinetics' lead pipeline candidate, atumelnant, which is currently in phase III development for congenital adrenal hyperplasia (CAH). The drug is also being developed in a mid-stage study for ACTH-dependent Cushing's syndrome. Beyond atumelnant, the acquisition will add several earlier-stage endocrine assets discovered using Crinetics' proprietary platform, further strengthening Vertex's long-term pipeline.
The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter. The company expects to fund the deal through a combination of cash and debt.
VRTX & CRNX Stock Performance
Post the announcement, shares of Vertex were slightly down in pre-market trading today, while those of Crinetics have jumped nearly 99%.
Year to date, VRTX’s stock is up nearly 17%, while CRNX is down about 10%. In comparison, the industry has risen 7% during this time frame.
Image Source: Zacks Investment Research
What Drives Vertex’s Interest in Crinetics?
While Vertex expects the acquisition to contribute immediately to revenue growth, it believes the deal will become accretive to adjusted operating income beginning in 2029.
The acquisition is expected to establish endocrinology as Vertex's fifth core therapeutic area, alongside cystic fibrosis, hematology, acute pain and renal diseases, further diversifying the company's rare disease portfolio. Management believes the transaction will add assets with a combined peak annual sales potential of more than $5 billion, driven by blockbuster sales potential for Palsonify and multibillion-dollar potential for atumelnant.
A key attraction for Vertex is atumelnant, which management believes could emerge as the new standard-of-care for CAH. During the conference call, executives highlighted its potential to achieve normal androgen levels while allowing patients to remain on physiologic glucocorticoid replacement doses. Vertex believes this profile could differentiate atumelnant from currently available therapies, including Neurocrine Biosciences’ (NBIX - Free Report) Crenessity, describing this combination of outcomes as the "holy grail" of CAH management.
Some analysts questioned Vertex on the significant premium offered for Crinetics. Management responded that the valuation reflects the intrinsic value of the company's commercial-stage and late-stage assets, noting that the purchase price is roughly twice the projected peak sales opportunity, which it considers appropriate for a portfolio with significant long-term growth potential.
View the Zacks #1 Rank List
Image: Bigstock
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
Key Takeaways
Vertex Pharmaceuticals (VRTX - Free Report) announced that it has agreed to acquire commercial-stage company Crinetics Pharmaceuticals . Per the terms, the large-cap biotech will acquire all outstanding shares of CRNX for $85 per share, valuing the deal at around $10 billion.
Following the acquisition, Vertex will add Palsonify — Crinetics’ first marketed drug and the first once-daily oral therapy for adults with acromegaly, a rare and debilitating condition caused by a pituitary tumor that secretes excess growth hormone. Approved by the FDA in September 2025 and across the EU in April 2026, Palsonify has demonstrated encouraging early commercial uptake and is expected to benefit from Vertex's global commercial infrastructure.
The company will also add several pipeline candidates, including Crinetics' lead pipeline candidate, atumelnant, which is currently in phase III development for congenital adrenal hyperplasia (CAH). The drug is also being developed in a mid-stage study for ACTH-dependent Cushing's syndrome. Beyond atumelnant, the acquisition will add several earlier-stage endocrine assets discovered using Crinetics' proprietary platform, further strengthening Vertex's long-term pipeline.
The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter. The company expects to fund the deal through a combination of cash and debt.
VRTX & CRNX Stock Performance
Post the announcement, shares of Vertex were slightly down in pre-market trading today, while those of Crinetics have jumped nearly 99%.
Year to date, VRTX’s stock is up nearly 17%, while CRNX is down about 10%. In comparison, the industry has risen 7% during this time frame.
Image Source: Zacks Investment Research
What Drives Vertex’s Interest in Crinetics?
While Vertex expects the acquisition to contribute immediately to revenue growth, it believes the deal will become accretive to adjusted operating income beginning in 2029.
The acquisition is expected to establish endocrinology as Vertex's fifth core therapeutic area, alongside cystic fibrosis, hematology, acute pain and renal diseases, further diversifying the company's rare disease portfolio. Management believes the transaction will add assets with a combined peak annual sales potential of more than $5 billion, driven by blockbuster sales potential for Palsonify and multibillion-dollar potential for atumelnant.
A key attraction for Vertex is atumelnant, which management believes could emerge as the new standard-of-care for CAH. During the conference call, executives highlighted its potential to achieve normal androgen levels while allowing patients to remain on physiologic glucocorticoid replacement doses. Vertex believes this profile could differentiate atumelnant from currently available therapies, including Neurocrine Biosciences’ (NBIX - Free Report) Crenessity, describing this combination of outcomes as the "holy grail" of CAH management.
Some analysts questioned Vertex on the significant premium offered for Crinetics. Management responded that the valuation reflects the intrinsic value of the company's commercial-stage and late-stage assets, noting that the purchase price is roughly twice the projected peak sales opportunity, which it considers appropriate for a portfolio with significant long-term growth potential.
Vertex Pharmaceuticals Incorporated Price
Vertex Pharmaceuticals Incorporated price | Vertex Pharmaceuticals Incorporated Quote
VRTX’s Zacks Rank
Vertex currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.